Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA), the most common chronic rheumatologic condition in childhood, remains a cause of significant morbidity, particularly in those with spondyloarthropathy, including psoriatic arthritis (PsA) and enthesitis-related arthritis (ERA). While secukinumab was recently appr...
Saved in:
Main Authors: | Meghan Corrigan Nelson DO (Author), Cynthia K. Manos MD, MSCE (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
by: Carmen García-, et al.
Published: (2013) -
EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)
by: E.I. Alexeeva, et al.
Published: (2006) -
EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)
by: E.I. Alexeeva, et al.
Published: (2006) -
COVID-19 after rituximab therapy in cSLE patients
by: Meghan Corrigan Nelson, et al.
Published: (2023) -
Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy
by: M. Gattinara, et al.
Published: (2011)